Takeaways: Mint’s expanded partnership with Bayer strengthens its position as a Canadian pharmaceutical distribution partner, broadening its footprint across cardiovascular and women’s health. T...
Bayer’s LYNKUET (elinzanetant) receives expanded authorization in Canada for breast cancer-related vasomotor symptoms Bayer Canada announced that Health Canada has expanded the market authorizat...
Takeaways: The expanded approval of Lynkuet for AET‑related VMS gives Canadian oncologists and breast cancer patients the first non‑hormonal, evidence‑based option specifically indicated for...
